Zydus Lifesciences shares were last seen 0.41 per cent up at Rs 891.55. At this price, the stock has slipped 8.43 per cent in ...

Zydus Lifesciences Ltd on Wednesday said it has received final approval from the US health regulator to manufacture the ...

The pharmaceutical company has been awarded the final approval for the manufacture of Niacin Extended-Release Tablets USP in ...

The non-flushing form of vitamin B3 ensures that users don’t experience the uncomfortable flushing that can come with other forms of niacin. This supplement also supports restful sleep and joint ...

Zydus Lifesciences rose 1.02% to Rs 897 after the pharma company received final approval from the US Food and Drug Administration (USFDA) to manufacture Niacin Extended-Release Tablets USP, 500 mg , ...

Ahmedabad: Zydus Lifesciences Limited has announced that the company has received final approval from the United States Food ...

Niacin, a B vitamin, has been prescribed for years to treat high cholesterol. Doctors often give it to patients along with statins to reduce the risk of heart disease. But a new study has noted ...

Niacin has long been used as an effective lipid-altering therapy, particularly for raising HDL-C and lowering triglyceride levels. In addition, niacin modestly lowers LDL-C levels. LDL-C ...

Niacin is an antihyperlipidemic agent, prescribed for hyperlipidemia. Cholestyramine can cause a decrease in the absorption of Niacin resulting in a reduced serum concentration and potentially a ...

Zydus Lifesciences Limited has earned USFDA approval for Niacin Extended-Release Tablets used to treat high cholesterol.

Zydus Lifesciences receives USFDA approval to manufacture generic Niacin extended-release tablets for lowering cholesterol.

Zydus Lifesciences has received final approval from the United States Food and Drug Administration (USFDA) to manufacture Niacin Extended-Release Tablets USP, 500 mg, 750 mg, and 1,000 mg (Niaspan ...